193 related articles for article (PubMed ID: 34087447)
1. A general prodrug nanohydrogel platform for reduction-triggered drug activation and treatment of taxane-resistant malignancies.
Yao J; Li T; Shi X; Wang Y; Fang S; Wang H
Acta Biomater; 2021 Aug; 130():409-422. PubMed ID: 34087447
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
Xie B; Wan J; Chen X; Han W; Wang H
Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
[TBL] [Abstract][Full Text] [Related]
3. Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.
Wan J; Huang L; Cheng J; Qi H; Jin J; Wang H
Theranostics; 2021; 11(9):4137-4154. PubMed ID: 33754053
[No Abstract] [Full Text] [Related]
4. Dimerization-induced self-assembly of a redox-responsive prodrug into nanoparticles for improved therapeutic index.
Zhou L; Xie H; Chen X; Wan J; Xu S; Han Y; Chen D; Qiao Y; Zhou L; Zheng S; Wang H
Acta Biomater; 2020 Sep; 113():464-477. PubMed ID: 32652227
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
6. Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models.
Li T; Chen X; Wan J; Hu X; Chen W; Wang H
Int J Pharm; 2021 Sep; 607():121017. PubMed ID: 34416334
[TBL] [Abstract][Full Text] [Related]
7. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
8. Transforming a highly toxic agent DM1 into injectable safe nanomedicines
Huang J; Song S; Wang M; Wang H
Nanoscale; 2023 Jun; 15(23):10110-10124. PubMed ID: 37255385
[TBL] [Abstract][Full Text] [Related]
9. Supramolecular nanoparticles self-assembled from reduction-responsive cabazitaxel prodrugs for effective cancer therapy.
Jin J; Wan J; Hu X; Fang T; Ye Z; Wang H
Chem Commun (Camb); 2021 Mar; 57(18):2261-2264. PubMed ID: 33532809
[TBL] [Abstract][Full Text] [Related]
10. Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts.
Shi L; Wang Y; Wang Q; Jiang Z; Ren L; Yan Y; Liu Z; Wan J; Huang L; Cen B; Han W; Wang H
J Control Release; 2020 Aug; 324():289-302. PubMed ID: 32442582
[TBL] [Abstract][Full Text] [Related]
11. Redox/pH dual-stimuli responsive camptothecin prodrug nanogels for "on-demand" drug delivery.
Qu Y; Chu B; Wei X; Lei M; Hu D; Zha R; Zhong L; Wang M; Wang F; Qian Z
J Control Release; 2019 Feb; 296():93-106. PubMed ID: 30664976
[TBL] [Abstract][Full Text] [Related]
12. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy.
Huang Z; Ding Y; Luo Y; Chen M; Zeng Z; Zhang T; Sun Y; Huang Y; Zhao C
Acta Biomater; 2022 Oct; 152():367-379. PubMed ID: 36084924
[TBL] [Abstract][Full Text] [Related]
13. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
14. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
[TBL] [Abstract][Full Text] [Related]
16. Reduction-Responsive Chemo-Capsule-Based Prodrug Nanogel for Synergistic Treatment of Tumor Chemotherapy.
Lu Y; Jia D; Ma X; Liang M; Hou S; Qiu W; Gao Y; Xue P; Kang Y; Xu Z
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8940-8951. PubMed ID: 33565847
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel, a new taxane with favorable properties.
Bouchet BP; Galmarini CM
Drugs Today (Barc); 2010 Oct; 46(10):735-42. PubMed ID: 21076710
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.
Barve A; Jain A; Liu H; Zhao Z; Cheng K
Acta Biomater; 2020 Sep; 113():501-511. PubMed ID: 32562805
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
[TBL] [Abstract][Full Text] [Related]
20. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
